Glucose variability: Timing, risk analysis, and relationship to hypoglycemia in diabetes

Diabetes Care

Volumn 39, Issue 4, 2016, Pages 502-510

  Kovatchev, Boris ^a   Cobelli, Claudio ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIXISENATIDE; PRAMLINTIDE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE;

BLOOD GLUCOSE MONITORING; CASE STUDY; CLINICAL FEATURE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; GLUCOSE METABOLISM; GLUCOSE VARIABILITY; HUMAN; HYPOGLYCEMIA; METABOLIC PARAMETERS; PANCREAS ISLET TRANSPLANTATION; PLOTS AND CURVES; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM; PRINCIPAL COMPONENT ANALYSIS; THEORETICAL MODEL;

BIOMARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MODELS, THEORETICAL; PEPTIDES; PRINCIPAL COMPONENT ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84962110910     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2035     Document Type: Review

References (51)

1. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN;DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascu-lar complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008; 57:995-1001
2. Santiago JV. Lessons from the Diabetes Control and Complications Trial. Diabetes 1993;42: 1549-1554
3. TheDiabetes Control and Complications Trial Research Group. The effect ofintensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypo-glycemia in diabetes. Diabetes Care 2005;28: 1245-1249
6. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46:271-286
7. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-948
8. Cryer PE. Glycemic goals in diabetes: tradeoff between glycemic control and iatrogenic hy-poglycemia. Diabetes 2014;63:2188-2195
9. McCall AL, Kovatchev BP. The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. J Diabetes Sci Technol 2009;3:3-11
10. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015;38:1610-1614
11. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015;38:1615-1621
12. Fernstrom JD. Branched-chain amino acids and brain function. J Nutr 2005;135(Suppl.): 1539S-1546S
13. Gelling RW, Overduin J, Morrison CD, et al. Effect of uncontrolled diabetes on plasma ghre-lin concentrations and ghrelin-induced feeding. Endocrinology 2004;145:4575-4582
14. German JP, Wisse BE, Thaler JP, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010;59:1626-1634
15. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hy-poglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973;182: 171-173
16. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregu-latory hormone release. Diabetes 1988;37: 901-907
17. Dagogo-Jack SE, Craft S, Cryer PE. Hypo-glycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hy-poglycemia. J Clin Invest 1993;91:819-828
18. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987;316:1376-1383
19. Cryer PE, Gerich JE. Glucose counterregula-tion, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med 1985;313: 232-241
20. White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hy-poglycemia during intensive therapy. N Engl J Med 1983;308:485-491
21. Cryer PE. Hypoglycemia: Pathophysiology, Diagnosis, and Treatment. Oxford University Press, 1997
22. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870-1875
23. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 2000;85:4287-4292
24. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypogly-cemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828
25. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care 2007;30:1370-1373
26. Pitsillides AN, Anderson SM, Kovatchev B. Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation. Diabetes Technol Ther 2011; 13:11-17
27. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565
28. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 1965;177:95-102
29. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655
30. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and gly-cemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955-962
31. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838-842
32. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes 2013;62:1405-1408
33. Fabris C, Facchinetti A, Sparacino G, et al. Glucose variability indices in type 1 diabetes: parsimonious set of indices revealed by sparse principal component analysis. Diabetes Technol Ther 2014;16:644-652
34. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997;20:1655-1658
35. Kovatchev BP, Straume M, Cox DJ, Farhy LS. Risk analysis of blood glucose data: a quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med 2000; 3:1-10
36. McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 2006;8:644-653
37. Kovatchev BP, Cox DJ, Straume M, Farhy LS. Association of self-monitoring blood glucose profiles with glycosylated hemoglobin in patients with insulin-dependent diabetes. Methods Enzymol 2000;321:410-417
38. Fabris C, Patek SD, Breton MD. Are risk indices derived from CGM interchangeable with SMBG-based indices? J Diabetes Sci Technol 2015;10:50-59
39. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438
40. Magni L, Raimondo DM, Man CD, et al. Evaluating the efficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol 2008;2:630-635
41. Clarke W, Kovatchev B. Statistical tools to analyze continuous glucose monitor data. Diabetes Technol Ther 2009;11(Suppl. 1): S45-S54
42. Service FJ. Glucose variability. Diabetes 2013;62:1398-1404
43. Rodbard D. The challenges of measuring glycemic variability. J Diabetes Sci Technol 2012;6:712-715
44. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253-263
45. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005;7:849-862
46. Kovatchev BP, Shields D, Breton M. Graphical and numerical evaluation of continuous glucose sensing time lag. Diabetes Technol Ther 2009;11:139-143
47. Kovatchev BP, Crean J, McCall A. Pramlin-tide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther 2008;10:391-396
48. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of gly-cemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009;11: 339-344
49. Umpierrez GE, DiGenio A, Goldenberg R, et al. Lixisenatide added to basal insulin reduces glycemic variability in T2DM patients (Abstract). Diabetes 2014;63(Suppl. 1):A260
50. Cobelli C, Man CD, Pedersen MG, Bertoldo A, Toffolo G. Advancing our understanding of the glucose system via modeling: a perspective. IEEE Trans Biomed Eng 2014;61:1577-1592
51. Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes 2014;63:1203-1213